Adaptive Biotechnologies Profit Margin 2018-2021 | ADPT
Current and historical gross margin, operating margin and net profit margin for Adaptive Biotechnologies (ADPT) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Adaptive Biotechnologies net profit margin as of June 30, 2021 is -128.33%.
|Adaptive Biotechnologies Annual Profit Margins
|Adaptive Biotechnologies Quarterly Profit Margins
||Medical - Biomedical and Genetics
Adaptive Biotechnologies Corporation is a commercial-stage biotech company. It develops and commercializes immune-driven clinical products to transform the diagnosis and treatment of disease. The company's product pipeline includes immunoSEQ, clonoSEQ and cellular therapy which are in clinical stage. Adaptive Biotechnologies Corporation is based in Seattle, Washington.